Michael D. Frost
Co-investigator on the EXIST-1 and EXIST-2 trials showing that the mTOR inhibitor everolimus shrinks tuberous sclerosis tumours in the brain and kidney
Pediatric neurologist/epileptologist, Minnesota Epilepsy Group, St. Paul, MN · child neurology fellowship, Univ. of Colorado (1977–1980) · MD, Saint Louis University (1975)
Minnesota Epilepsy Group (St. Paul, Minnesota, USA) ↗
Portrait: Minnesota Epilepsy Group
Sat on both pivotal EXIST trials: EXIST-1 (FRA2013) — everolimus shrank SEGA brain tumors ≥50% in 35% vs 0% placebo; EXIST-2 (BIS2013) — everolimus shrank kidney angiomyolipomas ≥50% in 42% vs 0% placebo.
Practices pediatric neurology/epilepsy at Minnesota Epilepsy Group; co-author of the 2021 International TSC Consensus Group diagnostic criteria update.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2013 | H | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial BIS2013 Site investigator on EXIST-2: everolimus shrinks kidney angiomyolipomas ≥50% in 42% vs 0% placebo. |
| 2013 | H | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial FRA2013 Site investigator on EXIST-1: everolimus shrinks SEGA brain tumors ≥50% in 35% vs 0% placebo. |
Co-authors in the Atlas 8
People with a profile here who share at least one study with Michael D. Frost.
ShowHide
- David Lebwohl 2 shared studies Medical oncologist and drug developer who led the clinical development of everolimus (Afinitor) at Novartis through approvals in several cancers and tuberous sclerosis, and later served as Chief Medical Officer of the gene-editing company Intellia Therapeutics
- Elena Belousova 2 shared studies Child neurologist and epilepsy specialist in Moscow who heads a department of psychoneurology and epileptology and has been a principal investigator in international drug trials for tuberous sclerosis complex
- Tarek Sahmoud 2 shared studies Physician and epidemiologist who worked as a clinical program head in Novartis oncology drug development during the everolimus trials, and later as chief medical officer at several cancer drug companies
- David N. Franz Led the EXIST-1 trial showing that the mTOR inhibitor everolimus shrinks the brain tumours (SEGAs) of tuberous sclerosis, and helped run the first sirolimus trial for its kidney tumours
- John J. Bissler Led the first clinical trial showing that the mTOR inhibitor sirolimus shrinks kidney angiomyolipomas in tuberous sclerosis, and the EXIST-2 trial of everolimus for the same tumours
- Klemens Budde Kidney and transplant physician who took part as an investigator in the EXIST-2 trial of everolimus for kidney tumours in tuberous sclerosis and LAM; clinician-investigator rather than a bench mTOR researcher.
- Sergiusz Jóźwiak A child neurologist known for work on tuberous sclerosis complex and a senior author of the EXIST-1 trial of everolimus.
- Vicky H Whittemore Neuroscientist and NIH program director for epilepsy and ME/CFS research who spent over two decades working for patient organisations, including the Tuberous Sclerosis Alliance
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.